Original language | English |
---|---|
Pages (from-to) | E159-E161 |
Journal | Diabetes care |
Volume | 42 |
Issue number | 10 |
DOIs | |
Publication status | Published - 2019 Oct 1 |
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Advanced and Specialised Nursing
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Effect of empagliflozin on endothelial function in patients with type 2 diabetes and cardiovascular disease : Results from the multicenter, randomized, placebo- controlled, double-blind EMBLEM trial. / Tanaka, Atsushi; Shimabukuro, Michio; MacHii, Noritaka et al.
In: Diabetes care, Vol. 42, No. 10, 01.10.2019, p. E159-E161.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Effect of empagliflozin on endothelial function in patients with type 2 diabetes and cardiovascular disease
T2 - Results from the multicenter, randomized, placebo- controlled, double-blind EMBLEM trial
AU - Tanaka, Atsushi
AU - Shimabukuro, Michio
AU - MacHii, Noritaka
AU - Teragawa, Hiroki
AU - Okada, Yosuke
AU - Shima, Kosuke R.
AU - Takamura, Toshinari
AU - Taguchi, Isao
AU - Hisauchi, Itaru
AU - Toyoda, Shigeru
AU - Matsuzawa, Yasushi
AU - Tomiyama, Hirofumi
AU - Yamaoka-Tojo, Minako
AU - Yoshida, Hisako
AU - Sato, Yasunori
AU - Ikehara, Yumi
AU - Ueda, Shinichiro
AU - Higashi, Yukihito
AU - Node, Koichi
N1 - Funding Information: Acknowledgments. The authors thank the investigators, coordinators, and patients who participated in the trial. They also thank Takeshi Morimoto (Hyogo College of Medicine, Nishinomiya, Japan), Mitsuyoshi Urashima (Jikei University School of Medicine, Tokyo, Japan), and Takashi Nomiyama (Fukuoka University, Fukuoka, Japan), who served as members of the independent data and safety monitoring committee for the trial. Duality of Interest. This study was funded by Boehringer Ingelheim and Eli Lilly and Company. A.T. received modest honoraria from Astellas, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Kowa, Merck, Mitsubishi Tanabe, Novo Nordisk, Taisho Toyama, Takeda, and Teijin. M.S. received an honorarium and endowed chair from Boehringer Ingelheim. H.T. received lecture fees from Bayer, Boehringer Ingelheim, Daichi Sankyo, Kowa, Takeda, Mitsubishi Tanabe, and Sanwa Kagaku Kenkyusho. Y.O. received lecture fees from Astellas, AstraZeneca, Merck Sharp & Dohme (MSD), Ono, Mitsubishi Tanabe, Bayer, Novo Nordisk, Eli Lilly and Company, Boehringer Ingelheim, Daiichi Sankyo, Kissei, Novartis, Kowa, and Sanwa Kagaku Kenkyusho and research Figure 1—The mean (SD) RHI at baseline and at the 24-week follow-up. RHI values were increased ([RHI at 24 weeks] − [RHI at baseline] . 0) after 24 weeks of treatment in 21 patients (45%) in the empagliflozin group (red lines) and 24 patients (47%) in the placebo group (blue lines).
PY - 2019/10/1
Y1 - 2019/10/1
UR - http://www.scopus.com/inward/record.url?scp=85072546608&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072546608&partnerID=8YFLogxK
U2 - 10.2337/dc19-1177
DO - 10.2337/dc19-1177
M3 - Letter
C2 - 31533913
AN - SCOPUS:85072546608
VL - 42
SP - E159-E161
JO - Diabetes Care
JF - Diabetes Care
SN - 1935-5548
IS - 10
ER -